Neuropathological and neuropsychological associations in hippocampal sclerosis of ageing; the 90+ study (P1.183)

Objective: To identify the relationship between hippocampal sclerosis (HS) and other common degenerative brain pathologies and to identify neuropsychological impairments associated with HS Background: Hippocampal sclerosis of ageing is a common neuropathological finding in the oldest-old who die with dementia. HS has a strong association with dementia (5 times stronger than Alzheimer’s disease (AD)) and during life, is commonly misdiagnosed as AD. Previous studies have consistently shown a relationship between TDP-43 and HS and conflicting associations between HS and other degenerative pathologies. Design/Methods: We studied 143 participants from the 90+ study, a population based study of people aged 90 and older (the oldest-old). Neuropathology data was available for HS, Alzheimer’s disease, TDP-43, Lewy body disease (LBD), arteriolosclerosis, atherosclerosis, and infarcts. We used Neuropsychological data closest to onset of cognitive impairment or death (for cognitively normal participants). We used regression analyses to study the associations between HS and other neuropathologies and to study the effect of neuropathologies on global and domain specific cognitive measures. Results: 96% (21/22) of participants with HS had dementia at death. In the whole sample, there was no difference in demographics between those with and without HS. Logistic regressions revealed TDP-43 (OR: 20.1, p Conclusions: In the oldest-old, HS is associated with TDP-43 and LBD but not AD. Differential involvement of cognitive domains in HS and TDP-43 vs. AD might help diagnosing HS during life. Study Supported by: NIA grant R01AG21055 Disclosure: Dr. Sajjadi has nothing to disclose. Dr. Corrada has nothing to disclose. Dr. Robinson has nothing to disclose. Dr. Kim has nothing to disclose. Dr. Trojanowski has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Johnson & Johnson. Dr. Kawas has nothing to disclose.